Literature DB >> 30080287

Lack of microRNA-155 ameliorates renal fibrosis by targeting PDE3A/TGF-β1/Smad signaling in mice with obstructive nephropathy.

Weiwei Xi1, Xuming Zhao1, Meijun Wu2, Wenjuan Jia1, Hua Li1.   

Abstract

Although microRNA-155 (miR-155) is implicated in the pathogenesis of several fibrotic diseases, information regarding its functional role in renal fibrosis is limited. The current study aims to investigate the effects of miR-155 on renal fibrosis in unilateral ureteral occlusion (UUO) mice. MiR-155 level was significantly increased in renal tissues of UUO mice and TGF-β1-treated HK2 cells. Masson's trichrome staining showed that delivery of adeno-associated virus encoding miR-155 inhibitor led to a decrease in renal fibrosis induced by UUO. The increased expression of plasminogen activator inhibitor type 1, collagen III and collagen IV was also inhibited after miR-155 inhibition. In addition, miR-155 knockdown also prevented TGF-β1-induced epithelial-mesenchymal transition, concomitantly with a restoration of E-cadherin expression and a decrease of vimentin expression. Computational analysis revealed that miR-155 directly targets at 3'UTR of PDE3A. Overexpression of miR-155 suppressed the luciferase activity and protein expression of PDE3A, whereas inhibition of miR-155 increased PDE3A luciferase activity and expression. Furthermore, miR-155 inhibited TGF-β1-induced the increase of TGF-β1 expression and Smad-2/3 phosphorylation in HK2 cells. In contrast, knockdown of PDE3A reversed the effect of miR-155 inhibition on TGF-β1 expression. This study demonstrates that knockdown of miR-155 attenuates renal fibrosis via inhibiting TGF-β1/Smad signaling activation by targeting the upstream molecule PDE3A. This study suggests that miR-155 inhibition may be a novel therapeutic approach for preventing fibrotic kidney diseases.
© 2018 International Federation for Cell Biology.

Entities:  

Keywords:  PDE3A; TGF-β1/Smad signaling; epithelial-mesenchymal transition; microRNA-155; renal fibrosis

Mesh:

Substances:

Year:  2018        PMID: 30080287     DOI: 10.1002/cbin.11038

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  4 in total

Review 1.  microRNA Crosstalk Influences Epithelial-to-Mesenchymal, Endothelial-to-Mesenchymal, and Macrophage-to-Mesenchymal Transitions in the Kidney.

Authors:  Swayam Prakash Srivastava; Ahmad Fahim Hedayat; Keizo Kanasaki; Julie E Goodwin
Journal:  Front Pharmacol       Date:  2019-08-16       Impact factor: 5.810

Review 2.  MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application.

Authors:  Linsey J F Peters; Jürgen Floege; Erik A L Biessen; Joachim Jankowski; Emiel P C van der Vorst
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

3.  In vivo therapeutic success of MicroRNA-155 antagomir in a mouse model of pulmonary fibrosis induced by bleomycin.

Authors:  Xiaoyuan Sun; Yu Kang; Shan Xue; Jing Zou; Jiabo Xu; Daoqiang Tang; Hui Qin
Journal:  Korean J Intern Med       Date:  2020-06-09       Impact factor: 2.884

Review 4.  Serum non-coding RNAs for diagnosis and stage of liver fibrosis.

Authors:  Chao Liu; Xueyun Hou; Kaixin Mo; Nannan Li; Cheng An; Guijian Liu; Zongdai Pan
Journal:  J Clin Lab Anal       Date:  2022-08-21       Impact factor: 3.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.